- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02224963
Macular Degeneration and Aging Study (MADAS)
Improving Care Planning and Well-being in Older Adults With Macular Degeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Loss of independence and valued activities places Age-related Macular Degeneration (AMD) patients at increased risk for depression, anxiety, and disability. Patients' emotional and behavioral responses to AMD can exacerbate the long-term health threat of the disease and contribute to preventable health care costs, loss of productivity, and burden to family members.This is a randomized controlled trial of a psycho-social intervention that addresses three mental health promotion goals: (1) increase emotional well-being, (2) improve future outlook, and (3) protect or enhance current and future-oriented functioning.
The trial examines the effects of the PREPSI for 250 AMD patients, 60 and older, regardless of actual vision acuity. All study participants receive 4 group-based vision education classes and resource information. Subjects are then randomized to Preventive Problem Solving Intervention (PREPSI) consisting of 8 sessions with certified problem-solving trainers or to an Enhanced Attention Control arm.
Assessors blind to treatment condition measure Psychological Well-being immediately post-intervention (Week 16) and at 6-month follow-up, Change in Future Outlook, including Preparation for Future Care from baseline to 16 week and 6-month follow-up, and Vision Functioning at 6 month follow-up. Measures include the Psychological Well-being Scale (Ryff & Keyes, 1995), the Preparation of Future Care Needs Scale (Sörensen & Pinquart, 2001), and the National Eye Institute Vision Functioning Questionnaire-25 (Stelmack, Stelmack, & Massof, 2002). The primary hypothesis is that PREPSI participants will report greater Psychological Well-being and more Preparation for Future Care immediately post-intervention (at 16 weeks) and at 6-month follow-up.
The PREPSI is a short, standardized modification of problem-solving therapy that trains participants to identify and clearly define current and future problems, and then generate, evaluate, choose, and implement solutions. The long-term goal of the investigators research program is to improve quality of life in late adulthood by conducting basic and translational research on preventive future planning.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of AMD
- 60 years and older
- Able to communicate in English.
Exclusion Criteria:
- Significant cognitive impairment at baseline (total score on Mini Mental State Exam (MMSE) for the Blind <18, equivalent to <21 in the regular MMSE);
- Residence in a nursing home (assisted living facilities are acceptable);
- Patient is acutely suicidal or psychotic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Preventive Problem-Solving Training
Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems.
It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
|
Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems.
It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
|
|
Active Comparator: Life and Health Review
Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention.
It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
|
Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention.
It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychological Well-being
Time Frame: at 16 weeks (immediately post-intervention)
|
The 42-item multidimensional Psychological Well-Being scale (PWB) will assess 6 dimensions of PWB: Autonomy, Environmental Mastery, Personal Growth, Positive Relations With Others, Purpose In Life, and Self-Acceptance.
The PWB is a Likert-scored self-report measure, with anchors of "1-disagree strongly" and "6-agree strongly."
|
at 16 weeks (immediately post-intervention)
|
|
Psychological Well-being
Time Frame: at 6-month follow-up
|
The 42-item multidimensional Psychological Well-Being scale (PWB) will assess 6 dimensions of PWB: Autonomy, Environmental Mastery, Personal Growth, Positive Relations With Others, Purpose In Life, and Self-Acceptance.
The PWB is a Likert-scored self-report measure, with anchors of "1-disagree strongly" and "6-agree strongly."
|
at 6-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Preparation for Future Care
Time Frame: from baseline to 16 weeks (immediately post-intervention)
|
Preparation for Future Care Measure (PFCM) consists of 29 items in five subscales that assess specific behaviors representative of each of five processes observed in PFC: Awareness of care needs, Gathering Information, Deciding on Preferences, Making Concrete Plans, and Avoidance.
It is rated on a fiv-point Likert Scale
|
from baseline to 16 weeks (immediately post-intervention)
|
|
Preparation for Future Care
Time Frame: at 6-month follow-up
|
Preparation for Future Care Measure (PFCM) consists of 29 items in five subscales that assess specific behaviors representative of each of five processes observed in PFC: Awareness of care needs, Gathering Information, Deciding on Preferences, Making Concrete Plans, and Avoidance.
It is rated on a fiv-point Likert Scale
|
at 6-month follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Silvia Sörensen, PhD, University of Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG 032032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular DegenerationRussian Federation
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hui PengNot yet recruitingNeovascular Age-related Macular Degeneration(nAMD)
-
Rophibio, Inc.Not yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Ocular Therapeutix, Inc.Duke University; FortreaActive, not recruitingNeovascular Age-Related Macular DegenerationUnited States, Argentina, Puerto Rico
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
-
Apellis Pharmaceuticals, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States, Australia
Clinical Trials on Preventive Problem-Solving Training
-
Dartmouth-Hitchcock Medical CenterCompleted
-
Ataturk UniversityPhd Nurgül KarakurtCompletedChild Development Disorders, Pervasive | Mother-Infant Interaction | Problems PsychosocialTurkey
-
University of RochesterNational Institutes of Health (NIH)Completed
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedColo-rectal CancerUnited States
-
Seattle Children's HospitalOregon Health and Science UniversityCompletedChronic Pain | Abdominal Pain | HeadacheUnited States
-
VA Office of Research and DevelopmentCompleted
-
University of Texas Southwestern Medical CenterHackensack Meridian Health; Kessler Institute for Rehabilitation; Baylor Health...CompletedCare Partners of Patients With Traumatic Brain Injury (TBI)United States
-
University of Alabama at BirminghamNational Eye Institute (NEI)Completed
-
Heidelberg UniversityGerman Federal Ministry of Education and ResearchCompletedSchizophrenia | Schizoaffective DisorderGermany
-
Children's Hospital Los AngelesCompletedStem Cell TransplantationUnited States